Cancer treatment: supportive care still needed

The treatment of cancer is shifting towards molecular targeted therapies, which are generally associated with fewer and milder side effects, indicating that the need for traditional supportive care measures may decrease in the future. However, these new products may be associated with their own unique set of side effects and supportive care measures will need to change to meet these requirements.

Published By Datamonitor

Celiac disease: improved diagnosis potential highlights untapped market

A new study has highlighted the benefit of routine antibody testing in suspected cases of celiac disease. While these data prove the merit of serological testing, awareness of the disease remains a significant issue. Indeed, with almost no treatment options available, the development of an effective pharmacological therapy offers the potential to reap significant returns from this untapped market.

Published By Datamonitor

Cell Therapeutics: pixantrone close to extending lymphoma treatment options

Having reported positive follow-up results for pixantrone from the pivotal Phase III EXTEND trial, Cell Therapeutics has now submitted a marketing application with the FDA for the drug in relapsed/refractory, aggressive non-Hodgkin's lymphoma. Pixantrone's chance of approval looks promising as it addresses an important unmet need for more effective third-line therapies in this population.

Published By Datamonitor

Cervical cancer: vaccines set to drastically reduce incidence

Despite a significant drop in the incidence of cervical cancer in the western world due to routine screening, cervical cancer remains the second most common cancer in women the world over. However, two new vaccines for the human papilloma virus (HPV), a major risk factor for cervical cancer, are set to have a dramatic impact on the incidence of cervical cancer all over the globe.

Published By Datamonitor

Changing of the guard in HIV treatment

The HIV market is forecast to grow from $7.1 billion in 2005 to an estimated $10.6 billion in 2015. This growth is to be driven by a combination of several factors, including an increase in the number of people diagnosed, and the launch of several new drugs and drug classes which offer new hope to patients who otherwise would have at-best limited, but perhaps no therapeutic options left at all.

Published By Datamonitor

Colorectal cancer: Amgen's pipeline drug set to overtake Erbitux

Published By Datamonitor

Concert: protease inhibitor holds potential to be prescribed un-boosted

US healthcare firm Concert Pharmaceuticals has initiated a Phase Ib study for its protease inhibitor CTP-518. Early data on the candidate suggest that, unlike many marketed protease inhibitors, it does not require ritonavir boosting. Datamonitor believes that if these results are confirmed in larger studies, the compound has a strong chance of gaining commercial success.

Published By Datamonitor

Cystic fibrosis: enzymes and antibiotics dominate the pipeline

Published By Datamonitor

Cystic fibrosis: phasing in new treatments

Published By Datamonitor

Cytotoxic therapies to feel sting of generics

Cytotoxic therapy has been the cornerstone of cancer treatment for many years: indeed, despite a number of unpleasant side effects, the therapy is relatively effective. However, because of this maturity in the market, generics companies remain keen to emulate the success of several cytotoxic brands that have attained blockbuster sales over the years.

Published By Datamonitor